These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16514969)

  • 1. [Treatment possibilities for patients with advanced prostate cancer].
    Gillessen S; Strasser F
    Ther Umsch; 2006 Feb; 63(2):157-62. PubMed ID: 16514969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Palliative and supportive treatment options in patients with advanced prostate cancer].
    Maurer T; Retz M; Gschwend JE
    Urologe A; 2007 Jan; 46(1):30-5. PubMed ID: 17211644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD; Crook JM; Lukka H
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer in the late 1990s: hormone refractory disease options.
    Moul JW; Lipo DR
    Urol Nurs; 1999 Jun; 19(2):125-31; quiz 132-3. PubMed ID: 10633763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teletherapy and radiopharmaceutical therapy of painful bone metastases.
    Silberstein EB
    Semin Nucl Med; 2005 Apr; 35(2):152-8. PubMed ID: 15765378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current controversies in the treatment of high-risk prostate cancer.
    Mitchell RE; Chang SS
    Curr Opin Urol; 2008 May; 18(3):263-8. PubMed ID: 18382235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hormone resistant prostate cancer.
    Fosså SD
    Acta Urol Belg; 1994 Apr; 62(1):73-6. PubMed ID: 7515211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy for colorectal carcinoma in the elderly].
    Kächele V; Hahn P; Adler G; Seufferlein T
    Z Gastroenterol; 2004 Oct; 42(10):1189-98. PubMed ID: 15508061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy.
    Gunawardana DH; Lichtenstein M; Better N; Rosenthal M
    Clin Nucl Med; 2004 Feb; 29(2):81-5. PubMed ID: 14734902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of metastatic prostate cancer: the crucial role of geriatric assessment.
    Droz JP; Chaladaj A
    BJU Int; 2008 Mar; 101 Suppl 2():23-9. PubMed ID: 18307689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for advanced prostate cancer: Looking through new lenses.
    Vogiatzi P; Cassone M; Claudio L; Claudio PP
    Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
    de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
    Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of advanced prostate cancer after first-line chemotherapy.
    Berthold DR; Sternberg CN; Tannock IF
    J Clin Oncol; 2005 Nov; 23(32):8247-52. PubMed ID: 16278480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
    El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S
    Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palliative treatment of skin metastases in dermato-oncology.
    Kähler KC; Egberts F; Gutzmer R
    J Dtsch Dermatol Ges; 2013 Nov; 11(11):1041-5; quiz 1046. PubMed ID: 24015966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.